1[1]Morson B.President's address.The polyp-cancer sequence in the large bowel.Proc R Soc Med 1974; 67:451-457
2[2]Winawer SJ,Zauber AG,Ho MN,O'Brien MJ,Gottlieb LS,Sternberg SS,Waye JD,Schapiro M,Bond JH,Panish JF.Prevention of colorectal cancer by colonoscopic polypectomy.The National Polyp Study Workgroup.N Engl J Med 1993; 329:1977-1981
3[3]Kato S,Fujii T,Koba I,Sano Y,Fu KI,Parra-Blanco A,Tajiri H,Yoshida S,Rembacken B.Assessment of colorectal lesions using magnifying colonoscopy and mucosal dye spraying:can significant lesions be distinguished? Endoscopy 2001; 33:306-310
7[7]General rules for clinical and pathological studies on cancer of the colon,rectum and anus.Part Ⅰ.Clinical classification.Japanese Research Society for Cancer of the Colon and Rectum.Jpn J Surg 1983; 13:557-573
4TSUKUMA H, AJIKI W. Descriptive epidemiology of colorectalcancer - international comparison[ J]. Nippon Rinsho, 2003,61 :25 -30.
5LABIANCA H,M0SC0NI S’GARASSINO M C. New strategics incolon cancer adjuvant therapy [J]. Annals of Oncology, 2006, 17(7):51 -54.
6LONGLCY D B,JOHNSTON P G. Molccular mcchanisms of drugrcsistancc[J].J Pathol ,2005,205(2) :275 -292.
7WOODLAND C,KORCN G,WAINCR I W’et al. Verapamil me-tabolites ;potential P - glycoprotcin - mediated multidrug resis-tance reversal agents[ J]. Can J Physiol Pharmacol,2003 ,81 (8):800-805.
8TAKAHA K,SAKACDA T,OKUMURA K. An update on overcom-ing MDR1 - mediated multidrug rcsistancc in canccr chemotherapy[J]. Curr Pharm(2006,12 (3) : 273 -286.
9LABIALLC S, GAYCT L, MARTHINCT F,et al. Transcriptionalregulators of the human multidrug resistance 1 gene: recent views[J]. Biochemical pharmacology,2002,64(5 -6) : 943 -948.
10SCHEFFER G L, KOOLM, HEUN M. Specific detection of mul-tidrug -resistance proteins MRP1,MRP2,MRP3,MRPS,andMDR3 P - glycoprotein with a panel of monoclonal antibodies[ J].Cancer Res, 2000,60:5269 -5277.
